7743-29-5

Usage

Uses

Used in Organic Synthesis:
[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl](triphenyl)phosphonium is utilized as a reactant in organic synthesis for its ability to participate in various chemical reactions, contributing to the formation of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, [3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl](triphenyl)phosphonium is used as a research compound to explore its potential in the development of new drugs, given its unique structure and reactivity.
Used in Material Science:
[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl](triphenyl)phosphonium is employed in material science as a component in the development of new materials, potentially enhancing their properties or creating novel materials with specific characteristics.
Used in Catalyst Development:
[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl](triphenyl)phosphonium is also used in the development of catalysts, where its phosphonium group may facilitate or enhance the catalytic activity in various chemical processes, improving the efficiency of reactions in industrial applications.

Upstream product

• 1074-82-4 potassium phtalimide 
• 5460-29-7 2-(3-bromopropyl)isoindole-1,3-dione 
• 603-35-0 triphenylphosphine 

Downstream Products

• 74591-95-0 (Z)-N-(4-(4-methylphenyl)but-3-enyl)phthalimide 
• 74591-97-2 cis-N-<4-(p-Nitrophenyl)-3-butenyl>phthalimide 
• 143741-67-7 N-(4-phenyl-3-butenyl)phthalimide 
• 74591-93-8 (Z)-N-(4-phenylbut-3-enyl)phthalimide 
• 211692-38-5 N-[4-(benzo[d]1,3-dioxol-5-yl)-3-butenyl]phthalimide 
• 211692-40-9 2-[(E)-4-(4-Methoxy-2,3-dimethyl-phenyl)-but-3-enyl]-isoindole-1,3-dione 
• 211692-41-0 2-[(E)-4-(4-Methoxy-naphthalen-1-yl)-but-3-enyl]-isoindole-1,3-dione 
• 211692-39-6 2-[(E)-4-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-but-3-enyl]-isoindole-1,3-dione 
• 74592-01-1 (Z)-4-p-Tolyl-but-3-enylamine; hydrochloride 
• 74592-03-3 (Z)-4-(3-Nitro-phenyl)-but-3-enylamine; hydrochloride 
• 1108733-03-4 (Z)-N-[4-(benzo[d]1,3-dioxol-5-yl)-3-butenyl]phthalimide 

Relevant academic research and scientific papers

6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER

The present invention discloses 6,7-dihydro-5H-pyrido[2,3- c]pyridazine, 1,2,3,4-tetrahydroquinoline, 1H-indole, 3,4- dihydro-2H-1,4-benzoxazine, 1H-pyrrolo[2,3-b]pyridin-1-yl, 7H- pyrrolo[2,3-c]pyridazine, 5H,6H,7H,8H,9H-pyridazino[3,4-b]azepine derivatives and related compounds of formula (I) as Bcl-xL protein inhibitors for use as pro-apoptotic agents for treating cancer, autoimmune diseases or immune system diseases. Formula (I). The description discloses the preparation of exemplary compounds (e.g. pages 113 to 354 examples 1 to 221) as well as pharmacological studies with relevant data (e.g. pages 355 to 367; examples A to E; tables 1 to 5). Exemplary compounds are e.g. 2-{6-[(1,3-benzothiazol-2-yl) amino]-1,2,3,4-tetrahydroquinolin-1-yl}-1,3-thiazole-4-carboxylic acid (example 1) or e.g. 3-{1-[(adamantan-1-yl)methyl]-5- methyl-1H-pyrazol-4-yl}-6-{3-[(1,3-benzothiazol-2-yl)amino]-4- methyl-5H,6H,7H,8H-pyrido[2,3-c]pyridazin-8-yl]pyridine-2-carboxylic acid (example 24).

BICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Benzazepine Dicarboxamide Compounds

This invention relates to novel benzazepine dicarboxamide compounds of the formula wherein R1 to R4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

AMIDE COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS

The present invention is directed to amide compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment or prevention of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, fibrotic, and low bone mass diseases, as well as cancer.

Synthesis and evaluation of N-alkyl-S-[3-(piperidin-1-yl)propyl] isothioureas: High affinity and human/rat species-selective histamine H 3 receptor antagonists

S-Alkyl-N-alkylisothiourea compounds containing various cyclic amines were synthesized in the search for novel nonimidazole histamine H3 receptor (H3R) antagonists. Among them, four N-alkyl S-[3-(piperidin-1-yl)propyl]isothioureas 18, 19, 22, and 23 were found to exhibit potent and selective H3R antagonistic activities against in vitro human H3R, but were inactive against in vitro human H 4R. Furthermore, three alkyl homologs 18-20 showed inactivity for histamine release in in vivo rat brain microdialysis, suggesting differences in antagonist affinities between species. In addition, in silico docking studies of N-[4-(4-chlorophenyl)butyl]-S-[3-piperidin-1-yl)propyl]isothiourea 19 and a shorter homolog 17 with human/rat H3Rs revealed that structural differences between the antagonist-docking cavities of rat and human H 3Rs were likely caused by the Ala122/Val122 mutation.

A σ1 receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.02,6.03,10.0 5,9.08,11]dodecan-3-ols (AHDs)

A library of N-substituted 4-azahexacyclo[5.4.1.02,6.0 3,10.05,9.08,11]dodecan-3-ols (AHDs) was synthesized and subjected to competition binding assays at σ1 and σ2 receptors, as well as off-target screening of representative members at 44 other common central nervous system (CNS) receptors, transporters, and ion channels. Excluding 3 low affinity analogs, 31 ligands demonstrated nanomolar Ki values for either σ receptor subtype. Several selective σ1 and σ2 ligands were discovered, with selectivities of up to 29.6 times for σ1 and 52.4 times for σ2, as well as several high affinity, subtype non-selective ligands. The diversity of structures and σ1 affinities of the ligands allowed the generation of a σ1 receptor pharmacophore that will enable the rational design of increasingly selective and potent σ1 ligands for probing σ1 receptor function.

OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF

The present application relates to novel alkylcarboxylic acids having an oxo-substituted azaheterocyclic partial structure, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

Convenient route to primary (Z)-allyl amines and homologs

A convenient two-step procedure for the synthesis of primary (Z)-allyl amines, (Z)-homoallyl amines [(Z)-but-3-enylamines], and (Z)-pent-4-enylamines using the Wittig reaction was achieved. The use of nonstabilized ylides from triphenylphosphonium salt, potassium salt, and apolar solvent produced (Z/E)-geometric isomer ratios generally greater than 1.6. The amine moiety was masked using a phtalimide group that was removed successfully in the last step of the process in two different conditions, NH2NH2/EtOH/rt or CH3NH2/EtOH/rt. However, in some cases, reduction of the C = C double bond in the deprotection with hydrazine was concomitantly observed. Copyright Taylor & Francis Group, LLC.

6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES

Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.

Novel H3 receptor antagonists. Sulfonamide homologs of histamine.

Sulfonamides derived from 4(5)-(omega-aminoalkyl)-1H-imidazoles containing chain lengths of three- to five-carbons were synthesized. Good to moderate H3 receptor binding affinities were observed for several butyl and pentyl homologs, whereas binding affinities were considerably weaker in the propyl series. Separation of the imidazole ring and the sulfonamide unit by a four- or five-carbon tether afforded potent H3 receptor antagonists.